All In Biotech

NDA 204781 · Guerbet

Dotarem

Gadoterate Meglumine · Intravenous

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Mar 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Mar 20, 2013

Approved uses

2

Original approval plus efficacy supplements

Registered trials

39

10 Phase 3, 8 recruiting

FAERS reports

3,261

2,312 serious, 64 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. DOTAREM is not approved for intrathecal use [see Warnings and Precautions ( 5.1 )] . Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of DOTAREM in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. The risk for NSF appears highest among patients with: Chronic, severe kidney disease (GFR < 30 mL/min/1.73 m 2 ), or Acute kidney injury....

What it is approved for

From the label in effect Mar 14, 2025.

DOTAREM is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. DOTAREM is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Mechanism: Gadoterate is a paramagnetic molecule that develops a magnetic moment when placed in a magnetic field. The magnetic moment enhances the relaxation rates of water protons in its vicinity, leading to an increase in signal intensity (brightness) of tissues. In magnetic resonance imaging (MRI), visualization of normal and pathological tissue depends in part on variations in the radiofrequency signal intensity that occurs with: differences in proton density differences of the spin-lattice or longitudinal relaxation times (T1) differences in the spin-spin or transverse relaxation time (T2) When...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • DOTAREM · GADOTERATE MEGLUMINE 1.8845GM/5ML (376.9MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • DOTAREM · GADOTERATE MEGLUMINE 5.6535GM/15ML (376.9MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • DOTAREM · GADOTERATE MEGLUMINE 37.69GM/100ML (376.9MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • DOTAREM · GADOTERATE MEGLUMINE 7.538GM/20ML (376.9MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • DOTAREM · GADOTERATE MEGLUMINE 3.769GM/10ML (376.9MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Gadoterate Meglumine" as an intervention, any sponsor and status, largest first.

All 39 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • urticaria612
  • dyspnoea488
  • nausea476
  • pruritus453
  • vomiting384
  • erythema376
  • cough270
  • rash253
  • product use in unapproved indication205
  • dizziness187
  • headache184
  • paraesthesia159

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20051
20061
20072
20082
20092
20105
20115
20127
201367
201466
2015221
2016225
2017258
2018395
2019313
2020333
2021264
2022220
2023237
2024239
2025194
2026202

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 32 on PubMed

Sponsor: Guerbet

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.